The Readout Loud

350 Episodio

1. 346: Zealand's obesity strategy and Immunovant's curious development plan

   Pubblicato: 20/03/2025
2. 345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies

   Pubblicato: 13/03/2025
3. 344: Trump's FDA commissioner nominee takes the hot seat

   Pubblicato: 06/03/2025
4. 343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs

   Pubblicato: 27/02/2025
5. 342: FDA cuts, zombie biotechs, and too much weight loss?

   Pubblicato: 20/02/2025
6. 341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

   Pubblicato: 13/02/2025
7. 340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

   Pubblicato: 06/02/2025
8. 339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

   Pubblicato: 30/01/2025
9. 338: Chinese biotechs, a WHO departure, and post-JPM thoughts

   Pubblicato: 23/01/2025
10. 337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

    Pubblicato: 15/01/2025
11. 336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

    Pubblicato: 09/01/2025
12. 335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

    Pubblicato: 19/12/2024
13. 334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

    Pubblicato: 12/12/2024
14. 333: An H5N1 bird flu update and talent scarcity in the radiopharma field

    Pubblicato: 05/12/2024
15. 332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

    Pubblicato: 21/11/2024
16. 331: AbbVie’s stumble, Amgen’s tumble and more election fallout

    Pubblicato: 14/11/2024
17. 330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

    Pubblicato: 07/11/2024
18. 329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

    Pubblicato: 31/10/2024
19. 328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

    Pubblicato: 24/10/2024
20. 327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

    Pubblicato: 17/10/2024